Send us a text

Tumor-agnostic therapies represent a radical shift in oncology. They abandon the traditional way of treating tumors based on cancer type and, instead, provide personalized options based on the genetic mutations. Today’s podcast is the 1st part of a 2-part series dedicated to agnostic treatments in cancer. Join us as Dr. Joshua Drago of Memorial Sloan Kettering Cancer Center shares his expertise about the agnostic approach to cancer care. In this episode he discusses agnostic research and points out the advantages as well as the treatment limitations of agnostic therapeutics.